Analytical Data
-
Gene name
PGGT1b
- Application
-
Alternative Names
PGGT1b；Geranylgeranyl transferase type-1 subunit beta
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P53609
-
Expression Region
1-377aa
-
AA Sequence
MAATEDERLA GSGEGERLDF LRDRHVRFFQ RCLQVLPERY SSLETSRLTI AFFALSGLDM LDSLDVVNKD DIIEWIYSLQ VLPTEDRSNL NRCGFRGSSY LGIPFNPSKA PGTAHPYDSG HIAMTYTGLS CLVILGDDLS RVNKEACLAG LRALQLEDGS FCAVPEGSEN DMRFVYCASC ICYMLNNWSG MDMKKAITYI RRSMSYDNGL AQGAGLESHG GSTFCGIASL CLMGKLEEVF SEKELNRIKR WCIMRQQNGY HGRPNKPVDT CYSFWVGATL KLLKIFQYTN FEKNRNYILS TQDRLVGGFA KWPDSHPDAL HAYFGICGLS LMEESGICKV HPALNVSTRT SERLLDLHQS WKTKDSKQCS ENVHIST
-
Molecular Weight
42.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PGGT1b, or protein geranylgeranyltransferase type I beta subunit, plays a crucial role in the post-translational modification of proteins, specifically in the geranylgeranylation of GTPase signaling proteins. This modification is vital for the proper localization and function of small GTPases, which are key regulators of numerous cellular processes, including growth, differentiation, and cytoskeletal dynamics. Dysregulation or mutations in PGGT1b or the geranylgeranylation process has been implicated in various diseases, particularly in cancer progression and metastasis, as well as in certain developmental disorders. As researchers seek to better understand the mechanistic pathways involving PGGT1b, recombinant PGGT1b proteins have become valuable tools for studying its enzymatic activity, identifying substrates, and exploring potential therapeutic targets. The production of PGGT1b as a recombinant protein allows for the detailed examination of its interactions and functional implications in various pathological contexts. This research is particularly relevant in the development of inhibitors that could provide novel strategies for cancer treatment by disrupting aberrant signaling pathways linked to PGGT1b activity, highlighting its significance in both basic biology and potential clinical applications.
